NEW YORK, April 6, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on XON, IOVA, JAGX, and JAZZ which can be accessed for free by signing up to www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com covers the Biotech sector, which harnesses
Shares in Germantown, Maryland-based Intrexon Corp. rose 2.25%, ending Thursday's trading session at $17.29. The stock recorded a trading volume of 1.28 million shares. The Company's shares have gained 9.85% in the last month and 22.80% over the last three months. The stock is trading 18.32% and 1.73% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Intrexon, which operates in the synthetic biology field in the US, have a Relative Strength Index (RSI) of 63.06.
On March 29th, 2018, ActoBio Therapeutics, a wholly owned subsidiary of Intrexon, and Intrexon T1D Partners LLC have been granted allowance by the US FDA for their Investigational New Drug application to initiate a Phase-Ib/IIa study for the treatment of early onset type 1 diabetes (T1D) with AG019, an innovative disease-modifying approach to induce immune tolerance in T1D. Get the full research report on XON for free by clicking below at: www.wallstequities.com/registration/?symbol=XON
San Carlos, California headquartered Iovance Biotherapeutics Inc.'s stock declined 4.32%, closing the day at $14.40 with a total trading volume of 882,469 shares. The Company's shares have surged 75.61% in the previous three months and 107.19% over the past year. The stock is trading 48.21% above its 200-day moving average. Additionally, shares of Iovance Biotherapeutics, which focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells, have an RSI of 36.77.
On March 12th, 2018, Iovance Biotherapeutics reported its Q4 and year-end 2017 results. For Q4 2017, GAAP net loss attributable to common stockholders was $25.9 million, and GAAP R&D expenses were $20.7 million. For the full year, GAAP net loss attributable to common stockholders was $92.1 million, and GAAP R&D expenses were $71.6 million. At December 31st, 2017, the Company held $145.4 million in cash, cash equivalents and short-term investments.
On March 13th, 2018, research firm B. Riley FBR, Inc. reiterated its 'Neutral' rating on the Company's stock with an increase of the target price from $18.50 a share to $22 a share. Access the free research report on IOVA now by signing up at: www.wallstequities.com/registration/?symbol=IOVA
San Francisco, California-based On Thursday, shares in Jaguar Health Inc. recorded a trading volume of 2.36 million shares. The stock ended the day 1.73% lower at $0.18. The Company's shares have advanced 30.69% in the past month and 33.68% in the previous three months. The stock is trading above its 50-day moving average by 7.83%. Furthermore, shares of Jaguar Health, which focuses on developing novel, sustainably derived gastrointestinal products for human prescription use and animals worldwide, have an RSI of 47.13.
On April 02nd, 2018, Jaguar Health announced that it has appointed Jonathan B. Siegel, a highly-experienced investment executive in the Pharmaceutical and Healthcare space, to the Company's board of directors. Siegel recently founded JBS Healthcare Ventures to pursue investments in public and private healthcare entities. Are you already registered with Wall St. Equities? Do so now for free, and get the report on JAGX at: www.wallstequities.com/registration/?symbol=JAGX
Dublin, Ireland headquartered Jazz Pharmaceuticals PLC's stock rose 1.62%, finishing yesterday's session at $152.61. A total volume of 609,785 shares was traded, which was above their three months average volume of 443,420 shares. The Company's shares have advanced 5.36% in the last month, 9.85% in the previous three months, and 6.56% over the past year. The stock is trading above its 50-day and 200-day moving averages by 3.49% and 4.48%, respectively. Additionally, shares of Jazz Pharma, which identifies, develops, and commercializes pharmaceutical products for various medical needs in the US, Europe, and internationally, have an RSI of 56.58.
On March 23rd, 2018, research firm H.C. Wainwright reiterated its 'Neutral' rating on the Company's stock with an increase of the target price from $150 a share to $160 a share. Aspiring Member, please take a moment to register below for your free research report on JAZZ at: www.wallstequities.com/registration/?symbol=JAZZ
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-biotech-stocks----intrexon-iovance-biotherapeutics-jaguar-health-and-jazz-pharma-300625509.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!